{"id":20911,"date":"2025-01-10T08:19:40","date_gmt":"2025-01-10T08:19:40","guid":{"rendered":"https:\/\/peraltafinancing.com\/business\/investing\/top-3-galectin-biotechs-set-to-surge-on-top-line-readout\/"},"modified":"2025-01-10T08:19:40","modified_gmt":"2025-01-10T08:19:40","slug":"top-3-galectin-biotechs-set-to-surge-on-top-line-readout","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=20911","title":{"rendered":"Top 3 Galectin Biotechs Set to Surge on Top Line Readout"},"content":{"rendered":"


\n<\/p>\n

\n

Topline clinical trial readouts typically represent binary events for biotech investors.\u00a0 If the company announces good trial data the stocks will typically gap up and hit a new equilibrium based on the stage of trial and their chances of getting an FDA approval. If the company announces bad data the stock gets crushed and investors can lose a lot or make a lot depending on whether or not they are short. Biotech stocks that have drugs that treat the same disease or have a similar way of treating patients also trade in sympathy with the company announcing.\u00a0 Then there are instances where biotech stocks that compete against each other in a certain disease will go up or down as the others in that sector do the opposite.\u00a0\u00a0<\/span><\/p>\n

Galectin Therapeutics (Nasdaq: GALT)\u00a0<\/b><\/p>\n

Has a major phase 2 readout in MASH cirrhosis due before the end of the year.\u00a0 The company telegraphed they would release this topline data after the Drug Safety Monitoring Board (DSMB) issued its final safety recommendation in December.\u00a0 The shorts are all over this stock claiming that the trial failed once before and will fail again and that dilution is coming. As shorts their job is to instill fear right before the readout and during the readout to hijack the message so they can realize profits.\u00a0 The longs have to see through the FUD and look at the facts the shorts are trying to distort.\u00a0 The first fact about GALT is that the chairman is a billionaire and has been funding this through notes at a modest 2.5% interest for the past 5 years so dilution is not a factor.\u00a0\u00a0<\/span><\/p>\n

The science is extremely sound and the market cap is a tiny $125 million compared to what they are about to announce. The risk reward is incredibly skewed toward the long term investor.\u00a0 If they fail the trial the billionaire will simply put in more money and go after the next indication.\u00a0 What you don\u2019t know about galectin science is that it has strong ties to blocking inflammation in at least 100 chronic diseases.\u00a0 So failure might result in a loss of 50% of your investment according to the shorts but if you are long this stock could be a multibagger in just weeks.\u00a0\u00a0<\/span><\/p>\n

The HC Wainwright analyst following this stock has an $11.00 price target which is a market cap of $700 million but that is small in comparison to its quasi competitor <\/span>Madrigal Pharmaceuticals (Nasdaq: MDGL)<\/b> which has a market cap of $6.7 billion.\u00a0 If GALT has a successful readout that leads to an quick approval MDGL might take a hit because they have a early stage MASH drug that people have to take for prevention even though there are no side effects in early MASH compared to MASH cirrhosis which is what GALT is reading out on.\u00a0\u00a0<\/span><\/p>\n

The statistics for their last trial back in 2017 indicates the drug is going to meet the endpoints this time because back then they had a hastily designed trial.\u00a0 This time the trial was designed really well and part of it was almost an exact repeat that got statistical significance back then but procedurally the FDA couldn\u2019t accept that data because it was after the fact.\u00a0 This clinical trial is essentially a procedural speed bump from the FDA.\u00a0 They basically passed the trial once and they should do it again this time with flying colors.\u00a0 The shorts are going to fry on this one if investors look at the premiums and open interest on the near term options.\u00a0\u00a0<\/span><\/p>\n

Bioxytran Inc. (OTCMarkets: BIXT)<\/b> also has a galectin blocker that can pretty much do the same thing GALT\u2019s drug does but it\u2019s an easier to take oral drug versus GALT\u2019s intravenous drug. An interesting aside is that the CEO of BIXT was also the CEO of GALT over 15 years ago.\u00a0 It\u2019s not hard to guess that his new drug is way better and finished its Phase 2 clinical trial for COVID19 with a 100% responders rate.\u00a0 Any good readout from GALT could boost BIXT because big pharma is going to want a pill versus an intravenous drug every 2 weeks.\u00a0 The only issue is that BIXT hasnt tested it in MASH but it won\u2019t matter to a pharma partner because both drugs inhibit the same target, galectin-3. The BIXT drugs also have no toxicity so they are shoe ins for approval. The market cap of BIXT is only $8 million and a screaming opportunity.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/p>\n

Galecto Biotech (Nasdaq: GLTO)<\/b> recently expanded their pipeline but they mainly have a galectin blocker going after MASH as well.\u00a0 They are GALT\u2019s nearest competitor.\u00a0 Expect a lot of institutional money to flow into the stock after the GALT readout either way.\u00a0 If it\u2019s good they are next in line to compete with an oral formulation and if it\u2019s bad they are next in line in MASH anyhow.\u00a0 The only issue to watch out for is that GLTO had a failed trial for toxicity but it was explainable.\u00a0 The market cap of GLTO is only $12 million.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/p>\n

\u00a0<\/p>\n

Conclusion<\/b><\/p>\n

Blocking galectins is a big business.\u00a0 This is probably some of the most disruptive technology in biotech.\u00a0 Remember how CAR-T cells were a thing, what about mRNA, well galectins are bigger than those two combined and there are only 3 public companies in the space.\u00a0 After GALT announces successful trial results all these stocks could levitate together. A basket buy of all three ahead of the readout makes the most sense but BIXT and GLTO are extremely undervalued. For investors looking for leverage and low risk high gain, GALT has options.\u00a0\u00a0\u00a0\u00a0\u00a0<\/span><\/p>\n

As always, investing in micro-cap stocks carries inherent risks, and it is crucial for investors to conduct thorough research and consider their risk tolerance. However, today\u2019s most active micro-cap stocks are worth keeping on your radar as they continue to generate significant market interest.<\/span><\/p>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"

Topline clinical trial readouts typically represent binary events for biotech investors.\u00a0 If the company announces good trial data the stocks will typically gap up and hit a new equilibrium based on the stage of trial and their chances of getting an FDA approval. If the company announces bad data the stock gets crushed and investors […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[96],"tags":[13713,13712,4827,13715,348,13714,213],"dealstore":[],"offerexpiration":[],"class_list":["post-20911","post","type-post","status-publish","format-standard","hentry","category-investing","tag-biotechs","tag-galectin","tag-line","tag-readout","tag-set","tag-surge","tag-top"],"yoast_head":"\nTop 3 Galectin Biotechs Set to Surge on Top Line Readout - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fivemor.com\/?p=20911\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Top 3 Galectin Biotechs Set to Surge on Top Line Readout - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"Topline clinical trial readouts typically represent binary events for biotech investors.\u00a0 If the company announces good trial data the stocks will typically gap up and hit a new equilibrium based on the stage of trial and their chances of getting an FDA approval. If the company announces bad data the stock gets crushed and investors […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fivemor.com\/?p=20911\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-10T08:19:40+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fivemor.com\/?p=20911#article\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/?p=20911\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\"},\"headline\":\"Top 3 Galectin Biotechs Set to Surge on Top Line Readout\",\"datePublished\":\"2025-01-10T08:19:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=20911\"},\"wordCount\":984,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"keywords\":[\"Biotechs\",\"Galectin\",\"Line\",\"Readout\",\"Set\",\"Surge\",\"Top\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fivemor.com\/?p=20911#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fivemor.com\/?p=20911\",\"url\":\"https:\/\/fivemor.com\/?p=20911\",\"name\":\"Top 3 Galectin Biotechs Set to Surge on Top Line Readout - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/#website\"},\"datePublished\":\"2025-01-10T08:19:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fivemor.com\/?p=20911#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fivemor.com\/?p=20911\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fivemor.com\/?p=20911#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fivemor.com\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Top 3 Galectin Biotechs Set to Surge on Top Line Readout\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fivemor.com\/#website\",\"url\":\"https:\/\/fivemor.com\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fivemor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fivemor.com\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/fivemor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fivemor.com\"],\"url\":\"https:\/\/fivemor.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Top 3 Galectin Biotechs Set to Surge on Top Line Readout - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fivemor.com\/?p=20911","og_locale":"en_US","og_type":"article","og_title":"Top 3 Galectin Biotechs Set to Surge on Top Line Readout - Som2ny Network","og_description":"Topline clinical trial readouts typically represent binary events for biotech investors.\u00a0 If the company announces good trial data the stocks will typically gap up and hit a new equilibrium based on the stage of trial and their chances of getting an FDA approval. If the company announces bad data the stock gets crushed and investors […]","og_url":"https:\/\/fivemor.com\/?p=20911","og_site_name":"Som2ny Network","article_published_time":"2025-01-10T08:19:40+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fivemor.com\/?p=20911#article","isPartOf":{"@id":"https:\/\/fivemor.com\/?p=20911"},"author":{"name":"admin","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371"},"headline":"Top 3 Galectin Biotechs Set to Surge on Top Line Readout","datePublished":"2025-01-10T08:19:40+00:00","mainEntityOfPage":{"@id":"https:\/\/fivemor.com\/?p=20911"},"wordCount":984,"commentCount":0,"publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"keywords":["Biotechs","Galectin","Line","Readout","Set","Surge","Top"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fivemor.com\/?p=20911#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fivemor.com\/?p=20911","url":"https:\/\/fivemor.com\/?p=20911","name":"Top 3 Galectin Biotechs Set to Surge on Top Line Readout - Som2ny Network","isPartOf":{"@id":"https:\/\/fivemor.com\/#website"},"datePublished":"2025-01-10T08:19:40+00:00","breadcrumb":{"@id":"https:\/\/fivemor.com\/?p=20911#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fivemor.com\/?p=20911"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fivemor.com\/?p=20911#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fivemor.com\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"Top 3 Galectin Biotechs Set to Surge on Top Line Readout"}]},{"@type":"WebSite","@id":"https:\/\/fivemor.com\/#website","url":"https:\/\/fivemor.com\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fivemor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fivemor.com\/#organization","name":"Som2ny Network","url":"https:\/\/fivemor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/fivemor.com"],"url":"https:\/\/fivemor.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/20911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20911"}],"version-history":[{"count":0,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/20911\/revisions"}],"wp:attachment":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20911"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=20911"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=20911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}